Study published in peer-reviewed journal finds BioStem’s products offer overall better treatment efficiency, and greater efficiency in general wound closure POMPANO BEACH, Fla., June 26, 2024 -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived allografts for advanced wound care, today announced that an article validating its proprietary processing method and its placental allograft...
![BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study](https://prismmediawire.com/wp-content/uploads/2024/05/Newsroom-May-2024-4.png)